Every story in this section, newest first — page 250 of 373.
Arcos Dorados Holdings (NYSE:ARCO), the world’s largest independent McDonald’s franchisee, reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
Intuitive Machines (NASDAQ:LUNR) reported its fourth-quarter and full-year 2025 financial results on March 19, 2026, marking a pivotal shift from a specialized lunar lander developer to a diversified space infrastructure powerhouse.
Destination XL Group (NASDAQ:DXLG), the largest omni-channel specialty retailer of big and tall men’s apparel, announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026.
Yiren Digital (NYSE:YRD) announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025, revealing a significant shift in operational strategy toward capital preservation and risk mitigation.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.
Darden Restaurants (NYSE:DRI) announced its financial results for the third quarter of fiscal 2026, ended February 22, 2026, reporting total sales of $3.345 billion.
Signet Jewelers (NYSE:SIG) today revealed its financial results for the fourth quarter and full fiscal year ended January 31, 2026, demonstrating steady operational execution in a normalizing luxury market.
Caleres (NYSE:CAL) reported financial results for the fourth quarter and full fiscal year ended January 31, 2026, highlighting a period of significant portfolio transformation and market share expansion.
Accenture (NYSE:ACN) reported solid financial results for the second quarter of fiscal 2026, ended February 28, 2026, characterized by steady revenue growth and robust demand for its strategic consulting and technology services.
DarioHealth (NASDAQ:DRIO) today announced its financial results for the fourth quarter and full year ended December 31, 2025, describing the period as a critical "foundation-building" year.
Cardinal Infrastructure Group (NASDAQ:CDNL) reported its financial results for the full fiscal year ended December 31, 2025, marking its first full year as a publicly traded entity with record-setting growth across all key metrics.
Canadian Solar (NASDAQ:CSIQ) reported its fourth-quarter and full-year 2025 financial results on March 19, 2026, highlighting a year of strategic transition toward high-growth energy storage and localized U.S. manufacturing.
ZKH Group (NYSE:ZKH), a leading digitalized industrial maintenance, repair, and operations (MRO) procurement platform in China, reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Duluth Holdings (NASDAQ:DLTH) reported a marked improvement in its financial health for the fourth quarter and full fiscal year ended February 1, 2026.
Shell (NYSE:SHEL) provided a critical update on its operations in Qatar following a series of security incidents at the Ras Laffan Industrial City.
Alibaba Group Holding (NYSE:BABA) announced its financial results for the quarter ended December 31, 2025, revealing a strategic pivot toward reinvestment and market share defense.
Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.
Almonty Industries (NASDAQ:ALM) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, highlighting a period of extreme valuation growth and strategic positioning.
Sunlands Technology Group (NYSE:STG) announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing a strategic transition from rapid scale to a quality-driven operational model.
UP Fintech Holding (NASDAQ:TIGR), known globally as Tiger Brokers, reported stellar financial results for the fourth quarter and full fiscal year ended December 31, 2025.
LexinFintech Holdings (NASDAQ:LX) today announced its unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025.
KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.
H World Group (NASDAQ:HTHT) reported strong unaudited financial results for the fourth quarter and full year ended December 31, 2025, underscored by significant portfolio growth and aggressive capital return programs.
